Cargando…

Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer

BACKGROUND: Circulating soluble programmed death ligand 1 (sPD-L1) can negatively regulate T-cell function and serve as a prognostic or predictive marker in a variety of cancers. However, rare studies have evaluated the potential roles of sPD-L1, and no study has estimated its predictive value for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yinjun, Zhang, Xiang, Zhu, Ming, He, Wenguang, Hua, Hanju, Ye, Feng, Zhou, Xile, Chen, Nan, Li, Yandong, Zhong, Weixiang, Wu, Guosheng, Cai, Hui, Jiang, Weiqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837921/ https://www.ncbi.nlm.nih.gov/pubmed/36639643 http://dx.doi.org/10.1186/s12967-023-03879-0

Ejemplares similares

Metastatic sites and lesion numbers cooperated to predict efficacy of PD‐1 inhibitor‐based combination therapy for patients with metastatic colorectal cancer
por: Jiang, Weiqin, et al.
Publicado: (2023)

Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy
por: Hua, Hanju, et al.
Publicado: (2023)

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
por: Jiang, Weiqin, et al.
Publicado: (2021)

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer
por: Liu, Shousheng, et al.
Publicado: (2019)

Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients
por: Liu, Shou-Sheng, et al.
Publicado: (2018)

Robust Glycogene-Based Prognostic Signature for Proficient Mismatch Repair Colorectal Adenocarcinoma
por: Li, Yixi, et al.
Publicado: (2021)

Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis
por: Xue, Wenxiu, et al.
Publicado: (2022)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
por: Eppenberger, Manuela, et al.
Publicado: (2010)

Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer
por: Swan, Rebecca, et al.
Publicado: (2016)

Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma
por: Giacomelli, Mauro, et al.
Publicado: (2023)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
por: Zhu, Jiangpeng, et al.
Publicado: (2023)

IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer
por: Rong, Yu-ming, et al.
Publicado: (2023)

Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers
por: Hale, Vanessa L., et al.
Publicado: (2018)

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2023)

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer
por: Jimenez-Rodriguez, Rosa M., et al.
Publicado: (2020)

Risk for Hereditary Neoplastic Syndromes in Women with Mismatch Repair-Proficient Endometrial Cancer
por: dos Santos, Jennifer Thalita Targino, et al.
Publicado: (2023)

The role of DNA mismatch repair in immunotherapy of human cancer
por: He, Yuchen, et al.
Publicado: (2022)

Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
por: Zhou, Guoying, et al.
Publicado: (2018)

Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy
por: Ho, William W., et al.
Publicado: (2021)

Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients
por: Jin, Min, et al.
Publicado: (2022)

Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2022)

Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
por: Matteucci, Laura, et al.
Publicado: (2023)

ASO Author Reflections: Clinical Outcome After Upfront Curative-Intent Local Treatment of Metastases in Patient with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer
por: Zwart, Koen, et al.
Publicado: (2023)

Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report
por: Chen, Mengni, et al.
Publicado: (2019)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

DNA mismatch repair in cancer immunotherapy
por: Guan, Junhong, et al.
Publicado: (2023)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)

Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study
por: Jary, Marine, et al.
Publicado: (2022)

Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study
por: Cheng, Yi-Kan, et al.
Publicado: (2022)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
por: Nehmé, A, et al.
Publicado: (1999)

Efficient engineering of chromosomal ribosome binding site libraries in mismatch repair proficient Escherichia coli
por: Oesterle, Sabine, et al.
Publicado: (2017)

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
por: Liu, Ding-Xin, et al.
Publicado: (2020)

Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers
por: Li, Jinming, et al.
Publicado: (2023)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
por: Zhao, Pengfei, et al.
Publicado: (2019)

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
por: Wensink, G. Emerens, et al.
Publicado: (2020)

Aspirin-induced nuclear translocation of NFκB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency
por: Din, F V N, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_212uinpr7ie1bdtdrs84vcslpg